Giant cell tumor of bone in the pediatric population: a retrospective study highlighting cases of metaphyseal only location and increased local recurrence rates in skeletally immature patients
Skeletal Radiology · 2023
DOI: 10.1007/s00256-023-04359-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Skeletal Radiology, 2023. Verfasst von Troy Q Tabarestani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Duke University School of Medicine, Duke University Hospital, 40 Duke Medicine Circle, Durham, NC, 27710, USA. tqt5@duke.edu. Hauptthemen laut MEDLINE: Giant Cell Tumor of Bone, Bone Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To describe the presentation of giant cell tumors (GCT) of the bone in the pediatric population to (1) improve the differential diagnosis of pediatric bone tumors and (2) identify the origin of GCT. Understanding the origin of bone tumors assists in establishing appropriate diagnoses and recommending treatment options. This is particularly important in children, where evaluating the need for invasive procedures is balanced with the desire to avoid overtreatment. GCT have historically been considered epiphyseal lesions with potential metaphyseal extension. Therefore, GCT may be inappropriately excluded from the differential diagnosis of metaphyseal lesions in the skeletally immature. MATERIALS AND METHODS: We identified 14 patients from 1981 to 2021 at a single institution who had histologic confirmation of GCT and were less than 18 years old at diagnosis. Patient characteristics, tumor location, surgical treatment, and local recurrence rates were collected. RESULTS AND CONCLUSIONS: Ten (71%) patients were female. Eleven (78.6%) were epiphysiometaphyseal (1 epiphyseal, 4 metaphyseal, 6 epiphysiometaphyseal). Five patients had an open adjacent physis, of which three (60%) had tumors confined solely to the metaphysis. Of the five patients with open physis, four (80%) developed local recurrence while only one patient (11%) with a closed physis had local recurrence (p value = 0.0023). Our results illustrate that for the skeletally immature, GCT can (and in our results more commonly did) occur in the metaphyseal location. These findings suggest that GCT should be included in the differential diagnosis of primary metaphyseal-only lesions in the skeletally immature.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Duke University School of Medicine, Duke University Hospital, 40 Duke Medicine Circle, Durham, NC, 27710, USA. tqt5@duke.edu.
- Department of Orthopedics, Duke University Hospital, Durham, NC, USA.
- Department of Pathology, Duke University Hospital, Durham, NC, USA.
- Department of Radiology, Duke University Hospital, Durham, NC, USA.
Zitieren
APA
Tabarestani, T. Q., Levine, N., Sachs, E., Scholl, A., Colglazier, R., French, R., Al-Rohil, R., Brigman, B., Eward, W., & Visgauss, J. (2023). Giant cell tumor of bone in the pediatric population: a retrospective study highlighting cases of metaphyseal only location and increased local recurrence rates in skeletally immature patients. Skeletal Radiology. https://doi.org/10.1007/s00256-023-04359-8
Vancouver
Tabarestani TQ, Levine N, Sachs E, Scholl A, Colglazier R, French R, et al. Giant cell tumor of bone in the pediatric population: a retrospective study highlighting cases of metaphyseal only location and increased local recurrence rates in skeletally immature patients. Skeletal Radiology. 2023. doi:10.1007/s00256-023-04359-8
BibTeX
@article{Tabarestani2023,
author = {Tabarestani, Troy Q and Levine, Nicole and Sachs, Elizabeth and Scholl, Ashley and Colglazier, Roy and French, Robert and Al-Rohil, Rami and Brigman, Brian and Eward, William and Visgauss, Julia},
title = {Giant cell tumor of bone in the pediatric population: a retrospective study highlighting cases of metaphyseal only location and increased local recurrence rates in skeletally immature patients},
journal = {Skeletal Radiology},
year = {2023},
doi = {10.1007/s00256-023-04359-8}
}
EUVIMED